The European Medicines Agency (EMA) appears willing to allow Actos, Takeda Pharmaceutical’s controversial diabetes drug, to remain on the market in Europe, though with new, more serious warnings regarding a potential bladder cancer risk. According to a report from SF Gate, the EMA’s Committee for Medicinal Products for Human Use has determined that the benefits [...]